UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported):
April 9,
2010
TRANSGENOMIC,
INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
000-30975
|
911789357
|
||
|
(State
of Incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification
|
||
|
Number)
|
||||
|
12325 Emmet Street,
Omaha, Nebraska
|
68164
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
(402) 452-5400
(Registrant’s
telephone number, including area code)
Not applicable
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
|
Item
5.02 Departure
of Officer.
Effective
as of April 9, 2010, Dr. Eric Kaldjian ceased to be the Chief Scientific Officer
of the registrant.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Dated: April
14, 2010
|
TRANSGENOMIC,
INC.
|
|
|
By:
|
/s/ Debra A.
Schneider
|
|
|
Debra
A. Schneider
|
||
|
Chief
Financial Officer
|
||